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Abstracts / Osteoarthritis and Cartilage 20 (2012) S10–S53S38Multivariate analyses showed that other signiﬁcant, independent
determinants of improvement in pain and function included age,
mental function score of the SF-12 and pre-operative pain and function
(both pain and function), as well as gender and BMI (function only).
Conclusions: The data suggest that we should exercise caution when
considering surgery for patients with severe pain but mild radio-
graphic changes, and conversely, that those with severe joint
damage, irrespective of which compartments are involved, are more
likely to respond well to surgery. A possible explanation for this is
that in those with severe pain and mild joint damage the pain is
driven more by central sensitisation than by any nociceptive input
from the joint.
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Purpose: To determine whether inhibition of inducible nitric oxide
synthase (iNOS) can slow progression of knee osteoarthritis (OA), using
the rate of joint space narrowing (JSN) in the medial tibiofemoral
compartment as the primary outcome measure.
Methods: This was a 2-year multinational, multicenter, double-blind,
parallel group trial enrolling subjects with symptomatic knee OA in
which subjects were randomly assigned to receive once daily 50 mg or
200 mg of the selective iNOS inhibitor, SD-6010, or placebo. Subjects
were required to have a bodymass index (BMI)25 and 40 kg/m2 and
Kellgren and Lawrence Grade (KLG) 2 or 3 in the study knee.
Randomization was stratiﬁed by KLG. Radiographs were acquired using
the modiﬁed Lyon-schuss protocol, at baseline, 48 and 96 weeks for
measuring JSN. Clinical beneﬁt was recorded at 12-week then every 24
weeks; use of acetaminophen, NSAIDs and/or weak opioids was
permitted throughout the trial. The primary analysis of the rate of JSN
used a continuous time random coefﬁcients MMRM model. The slope
over the entire 96 week period was used to assess the rate of change in
joint space width (JSW).
Results: Of 1457 randomized subjects (SD-6010 50mg, n¼485; SD-6010
200mg, n¼486; placebo, n¼486), 1048 (71.9%) completed the study.
Subjects were predominantly female (76.5%) with mean age 61.
0 years and mean BMI of 31.8 kg/m2. Fifty-six percent had KLG3. The
primary analysis did not demonstrate the superiority of SD-6010 in
either treatment group over placebo. In an exploratory discrete time
MMRM analysis of KLG2 subjects, the loss of JSW after 48 weeks was
signiﬁcantly smaller with SD-6010 (50 mg or 200 mg) than placebo.
Least squared (LS) mean  standard error (SE) losses in JSW for SD-
6010 50mg (-0.048  0.028 mm) and 200mg (-0.062  0.028 mm)
were 59.9% (95% CI: 6.8%, 106.9%) and 48.7% (95% CI: -8.4%, 93.9%) of
placebo (-0.120  0.028 mm; P¼0.032 and P¼0.081, respectively).
After 96 weeks, the LS mean losses in JSW for SD-6010 50mg (-0.132
 0.036 mm) and 200mg (-0.156  0.037 mm) were 20.9% (95% CI:
-50.5%, 64.0%) and 6.8% (95% CI: -72.7%, 51.7%) of the LS-mean JSW
loss in the placebo group (-0.1670.036 mm) (P¼0.460 and P¼0.812,
respectively). In a similar analysis of KLG3 subjects, no improvement
in JSN was observed. Although SD-6010 showed no efﬁcacy with
respect to improvement in joint pain or function, it was generally safe
and well tolerated in this population.
Conclusions:During the ﬁrst 48 weeks of treatment, subjects with mild
OA who were treated with an iNOS inhibitor had a lower rate of JSN;
however, this improvement was not sustained at 96 weeks. iNOS
inhibition did not slow OA progression in subjects with more severe
radiographic OA. The observed early effect on JSN in subjects with mild
OA supports the role of iNOS in OA pathogenetic mechanisms. However,
the loss of efﬁcacy over time and the lack of effect in subjects with more
severe disease suggest that alternative biochemical catabolic pathways
overcame the effects of nitric oxide inhibition alone or that in more
severe radiographic OA, biomechanical factors may not be amenable to
iNOS inhibition.57
INFLAMMATORY BIOMARKERS OF OA, IL-6 AND LEPTIN ARE
MODIFIABLE IN OVERWEIGHT/OBESE OA PATIENTS WITH
A PROTOCOL THAT COMBINES TRAINING IN PAIN COPING SKILLS
AND WEIGHT MANAGEMENT
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Purpose: A randomized clinical trial to investigate the effect of
a combined pain coping skills training and lifestyle behavioral weight
management protocol, on knee pain and disability as well as systemic
biochemical markers, in overweight and obese patients with knee
osteoarthritis.
Methods: Eligibility for the OA LIFE study enrolled participants with
self-reported knee pain who were overweight or obese, met the ACR
criteria for knee OA, and had radiographic evidence of OA in at least one
knee. A total of 232 participants were enrolled in the study and
randomized to one of four treatment groups:1) pain coping skills
training alone (PCST-only), 2) behavioral weight loss alone (BWL-only)
3) PCST with BWL (PCST+BWL), or 4) standard care control (SC). Blood
and urine were collected for biomarker analyses and questionnaires
obtained to assess pain, physical disability, stiffness, activity, psycho-
logical disability (WOMAC, AIMS). Following a 24 week treatment
period, 63 of the participants dropped out prior to completing the
treatment protocol. The remaining 169 subjects completed a post-
treatment clinical assessment and biospecimen collection. Samples
were analyzed for inﬂammatorymarkers (hsCRP, IL-1ra, IL-1b, IL-6, IL-8,
TNF-a, TNFR1 and TNFRII), adipokines (leptin and adiponectin), and
joint biomarkers (HA) by immunoassay. Data are reported as mean (SD)
and theWilcoxon test used to compare biomarker levels at baseline and
after treatment. Values for cytokines were log transformed and corre-
lations were tested with Pearson correlation test. Multivariable
regression analysis was used to assess the effects of treatment group on
the change in biomarker levels during treatment and adjusted for age,
race, gender, and BMI. All analyses were performed using SAS and a p
value of <0.05 was considered statistically signiﬁcant.
Results: Our study population consisted of 169 overweight or obese
patients who were 83% female, 60% white, having a mean (SD) age of
58.70 (10.0) years and a mean (SD) BMI of 34.10 (4.42) at baseline. As
reported previously, patients randomized to PCST+ BWM demonstrated
signiﬁcantly better treatment outcomes in terms of pain and weight
loss when compared to the other three conditions (p¼ <0.05). Analyses
conducted for the present paper comparing mean biomarker levels
before and after treatment revealed signiﬁcant reductions in levels of
hsCRP (p¼0.0014), IL-6 (p¼0.0075), and leptin (p¼0.0001) for the
combined intervention group (PCST+BWL). Adjusting for age, race,
gender, BMI, and baseline biomarker concentration, there were signif-
icant reductions in leptin (b¼-0.19175, p¼0.0120) and IL-6 (b¼-0.25036,
p¼0.0232) in response to only the combined PCST+BWL treatment.
Reductions in both IL-6 and leptin, regardless of the treatment group,
were signiﬁcantly associated with a reduction in WOMAC pain scores.
Changes in IL-6 were also signiﬁcantly associated with changes in
WOMAC physical function score (r¼0.198, p¼0.014) and AIMS physical
disability score (r¼0.192, p¼0.018) and changes in leptin were signiﬁ-
cantly associated with changes in AIMS pain score (r¼0.165, p¼0.040).
Conclusions: This is the ﬁrst study to investigate the effects of
combined pain coping skills training and behavioral weight manage-
ment protocol on biomarkers of inﬂammation in overweight and obese
OA patients. Participants receiving this protocol were not only
successful in signiﬁcantly reducing their pain and weight, but this was
accompanied by signiﬁcant reductions in inﬂammatory markers with
known associations with OA severity. The signiﬁcant reduction in
weight experienced by the combined treatment group is likely the
source of the changes in inﬂammatory state, as adipose tissue is
a known source of inﬂammatory cytokines/adipokines, such as IL-6 and
leptin. This study demonstrated that this inﬂammatory state can be
successfully modiﬁed with behavioral intervention resulting in positive
clinical outcomes.
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ABNORMAL PROCESSING OF TYPE II COLLAGEN IN CARTILAGE-
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